Low Glycemic Index Treatment in pediatric refractory epilepsy: The first Middle East report  by Karimzadeh, Parvaneh et al.
Seizure 23 (2014) 570–572Short communication
Low Glycemic Index Treatment in pediatric refractory epilepsy:
The ﬁrst Middle East report
Parvaneh Karimzadeh a,b, Mostafa Sedighi b,1, Maryam Beheshti c,*, Enzollah Azargashb a,
Mohammad Ghofrani a,b, Fatemeh Abdollahe-Gorgi d
a Paediatric Neurology Research Center, Moﬁd Children’s Hospital, Tehran, Iran
bDepartment of Paediatric Neurology, Moﬁd Children’s Hospital, Tehran, Iran
cDepartment of Nutrition, Moﬁd Children’s Hospital, Tehran, Iran
dClinical Research Development Center, Moﬁd Children’s Hospital, Tehran, Iran
A R T I C L E I N F O
Article history:
Received 27 June 2013
Received in revised form 18 March 2014
Accepted 20 March 2014
Keywords:
Low Glycemic Index Treatment
Refractory epilepsy
Ketogenic diet
Children
Seizure reduction
A B S T R A C T
Purpose: Intractable epilepsy is a challenging aspects of pediatric epilepsy. This study was conducted to
determine the efﬁcacy and tolerability of Low Glycemic Index Treatment (LGIT) in pediatric patients
referred to a Children’s Hospital in Iran with intractable epilepsy.
Methods: We studied 42 children with refractory epilepsy aged between 1.5 and 17 years of age, from
October 2009 to April 2011 in the pediatric neurology department of Moﬁd Children’s Hospital. Patient
information on clinical status, seizure type, and baseline frequency, blood and urine biochemistry,
neuro-imaging and the EEG were collected. LGIT was initiated on an outpatient basis and the diet was
composed of 65% fat, 25% protein and 10% carbohydrate (40–60 g), and the glycemic index of foods was
limited to below 50.
Results: 84% of patients were categorized as having more than one seizure per day at study entry, with
the remaining children as experiencing over one seizure per week. A greater than 50% seizure reduction
was observed in 71.4% of the patients after the second week, in 73.8% at the end of the ﬁrst month and in
77.8% at the end of the second month. In 30% of the patients a mild increase in blood urea nitrogen (BUN)
was detected. The most important reasons for discontinuation of LGIT were restrictiveness, lack of
satiation and excessive meat in this diet. No signiﬁcant complications were observed during the
administration of the diet.
Conclusion: LGIT is a safe and effective adjuvant antiepileptic therapy and may be used as an alternative
to the ketogenic diet in conditions when this diet cannot be used.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Refractory epilepsy is a challenging aspect of pediatric epilepsy
and there remain many patients who are refractory to new and
advantageous antiepileptic drugs.1 However, surgery is beneﬁcial
to a limited number of these patients.2 Hence, one available option
is from dietary treatments. The classic ketogenic diet (KD) is
effective in over a 90% seizure frequency reduction in one-third
of patients with refractory epilepsy3; however, there are* Corresponding author at: Department of Nutrition, Shahid Beheshti University
of Medical Sciences, Moﬁd Children’s Hospital, Shariati Avenue, Tehran
1546815514, Iran. Tel.: +98 2126406018; fax: +98 2122909559.
E-mail addresses: meheshti@gmail.com, maryam.beheshti@yahoo.com
(M. Beheshti).
1 Present address: Kermanshah Children’s Hospital, Kermanshah, Iran.
http://dx.doi.org/10.1016/j.seizure.2014.03.012
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reseveral limitations to its availability, implementation, and
maintenance.4–7
Considering this, alternative treatments are necessary. The Low
Glycemic Index Treatment (LGIT) and the Modiﬁed Atkins Diet
(MAD) are diets recently introduced for refractory epilepsy.5,7 LGIT
has an antiepileptic efﬁcacy comparable to KD with fewer side
effects.7
For the ﬁrst time in Iran, we have used LGIT for children with
refractory epilepsy to assess its efﬁcacy, tolerability, and side effects.
2. Materials and methods
This clinical trial study was conducted at the department of
pediatric neurology of Moﬁd Children’s Hospital on pediatric
patients with refractory epilepsy, between September 2010 and
July 2011. The exclusion criteria were as follows: (1) Unknownserved.
Fig. 1. Percent seizure reduction, compared with baseline, at 2, 4 and 8 weeks.
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treatment with the KD in the previous 5 months because of the
residual effects of KD on seizure controls; and, lastly, (3) a history
of metabolic or nephrologic problems.
The patients and their parents were educated by the dietician
regarding the restriction of carbohydrates with high glycemic
index (GI > 50) and limiting total carbohydrates to 40–60 g/day
(roughly 10% of daily calories).7
Patient height, weight, and Laboratory assessments (blood
glucose, b-hydroxybutyrate, blood urea nitrogen (BUN), creati-
nine, triglyceride, cholesterol, serum transaminases, urine speciﬁc
gravity, and ketone bodies with urine Ca/Cr ratio) at baseline and at
each follow-up visit were documented. A neurologist documented
seizure type, baseline seizure frequency, and prior and current
antiepileptic drugs. All possible side effects were questioned
during follow up visits.
3. Results
The 42 patients included in this study were aged between 1.5
and 17 years of age (mean, 5.6  3.2 years), with an equal number of
male and female patients. All patients were considered to have
refractory epilepsy with a history of more than three antiepileptic
drugs without effective seizure control. While on the diet, patientsTable 1
Biochemical changes and its relationship with efﬁcacy.
Biochemistry Before LGIT
mean  SD
After LGIT
mean  SD
Serum glucose 77.1  16.8 mg/dl 72.8  14.3 m
BUN 13.9  7.5 mg/dl 17.7  10.3 m
Creatinine 0.64  0.11 mg/dl 0.65  0.13 m
Triglycerides 85.2  24 mg/dl 96  30.5 m
Cholesterol 132  37.2 mg/dl 146  42.5 m
AST 27.8  9 mg/dl 27.8  8.6 m
ALT 27.9  11 mg/dl 31  14.3 mconsumed 2–4 (mean 2.9  0.6) AEDs. Seizure frequency was
between one seizure per week to over 100 seizures per day with a
median of 3.00 per day. The duration of LGIT was between 4 and 44
weeks (mean 15.3  11.2 weeks; median 12.0).
The aetiologies of epilepsy were cryptogenic (59%), sequela of
remote insult (24%), structural anomalies (7%), and idiopathic
(10%).
Mean seizure frequencies at weeks 2, 4, and 8 after treatment
started were signiﬁcantly lower than the baseline (p < 0.001)
with reduction rates of 56%, 61%, and 67%, respectively. Fig. 1
depicts the percentage of patients according to the percent of
seizure reduction for each given interval. The efﬁcacy of seizure
reduction (>50%) was 71.4%, 73.8%, and 77.8% after 2, 4, and 8
weeks, respectively. The percentage of seizure free patients
increased to 9.5%, 14.3%, and 16.6% at weeks 2, 4 and 8,
respectively, with increasing duration of treatment. Seizure type
did not have a signiﬁcant effect on efﬁcacy (p = 0.75). There was
no correlation between the age, sex, type, and aetiology of
seizure, EEG, and imaging ﬁndings with the effectiveness of LGIT
(p = 0.70, p = 0.19, p = 0.75, p = 0.44, p = 0.60, and p = 0.85,
respectively).
Reasons for discontinuation of the diet were as follows:
restrictiveness (n = 8); lack of satiation (n = 7); premature discon-
tinuation due to orders of physicians out of our centre who wereP value Relationship of the
biochemical changes
with efﬁcacy (Spearman’s
correlation) (P value)
g/dl 0.005 0.421
g/dl 0.001 0.196
g/dl 0.38 0.38
g/dl 0.001 0.355
g/dl 0.136 0.224
g/dl 0.91 0.321
g/dl 0.087 0.879
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dissatisfaction of parents with the amount of efﬁcacy (n = 3); and
shifting to surgical options (callosotomy, n = 1).
There was no notable change in drug regimen for patients
during treatment. No signiﬁcant complications during the course
of treatment were reported, except for a 4-year-old child that had a
previous history of nephrolithiasis that led to treatment discon-
tinuation after 18 weeks of treatment and despite signiﬁcant
seizure reduction.
Baseline and follow-up assessments of serum glucose, BUN,
creatinine, triglycerides, cholesterol, AST, and ALT levels were
available for 15 patients (Table 1).
Serum ketone bodies were available in two patients with
normal results (0.1 and 0.2 mmol/dl). Urine ketone bodies were
also quantitatively analyzed in 12 patients and 3 patients had +1
ketone bodies detected in their urine. The mean urine speciﬁc
gravity in these patients revealed a relative increase of urine
concentration (speciﬁc gravity = 1.023).
It needs to be mentioned that these results had been obtained
from different laboratories.
4. Discussion
Our ﬁndings suggest that LGIT can reduce seizure frequency in a
large number of patients with refractory epilepsy. Following a one-
year course of follow up, Muzykewics et al.6 found an over 50%
reduction in up to 66% of their patients when compared to baseline
seizure frequency. They also found that lower glucose levels were
associated with better seizure control with no correlation with
serum ketone bodies. Coppola et al.8 also indicated that 8 of their
15 (53.3%) patients experienced a 50–90% seizure reduction after a
mean follow up period of 14.5  6.5 months. Their ﬁndings
conﬁrmed the association between plasma glucose levels and seizure
control reported by Muzykewics et al.6 Pfeifer et al. have suggested
that it is the reduced blood glucose, and not the level of ketosis that
produces the anti-epileptic effect of KD and LGIT.4 Our study found no
association between random glucose levels and seizure control.
However, the results obtained were from different laboratories and
we had limitations in testing serum ketone bodies. Muzykewics et al.6
found elevated serum BUN levels in more than one-third of the
patients, as we observed in our study.
In our experience, LGIT had fewer side effects when compared
to KD, a characteristic that is of great value for young children. In
this study, we observed a 12.6% increase in serum triglycerides
without signiﬁcant metabolic implication, an increase close to
12.5% as reported by Thibert et al.9 and attributed to high fat
content in the diet. It was assumed that this increase in triglyceride
levels will not be a disadvantage for LGIT, because the highest
triglyceride level detected was 150 mg/dl (within the normal
range). Although we observed elevated BUN levels in approxi-
mately one-third of patients that were probably the result of
protein intake, there is likely no relationship between excessive
protein intake and kidney failure in normal subjects. Hence, pre-
existing renal failure is a contraindication of LGIT diet. Elevated
urine speciﬁc gravity in our patients may have also increased BUN
levels. Therefore, it is recommended that LGIT patients be closely
followed for renal function, higher ﬂuid intake, and modiﬁcations
in protein intake if necessary.
In our study, in terms of compliance and tolerability, LGIT was
more palatable and better tolerated than KD. However, despite the
restrictiveness of KD, a similar study conducted earlier at our
centre on KD patients showed that they stayed on the treatment for
a longer duration,10 a difference with several explanations. First,
KD patients are hospitalized, which provides them with sufﬁcient
time for education and availability of the emergent medicalintervention to relieve anxiety and leads to greater parental
conﬁdence. However, in LGIT, this intervention is absent and may
cause early treatment discontinuation. Parents consider KD a last
resort in the treatment of their child’s refractory epilepsy and they
rigidly follow the instructions for KD. Finally, the effect of KD
appears earlier than LGIT, which provides a strong motivation to
continue treatment.10–12
In conclusion, LGIT was better tolerated and more palatable
than KD. Easy preparation without detailed meal plans and
weighing food on a gram scale, increased palatability because of
more liberalized carbohydrate content and decreased fat content
are some advantages of LGIT. Finally, yet importantly, we may add
fewer psychosocial issues as the normality of the foods and ability
of the patients to eat outside the home without the need to prepare
special meals. The low cost of the outpatient implementation of
LGIT is a main advantage of this treatment. However, this is at the
expense of less than optimal intervention and communication
with patients and parents.
Based on these observations, it may be better for some patients
and in some special situations to introduce LGIT in a hospital
setting with a primary fasting state like KD.
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